Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Taro Shareholders Vote “FOR” Taro Sun Pharma Merger
Taro’s shareholders are reminded that the
To vote their shares, shareholders should refer to the proxy card that was mailed to them commencing
Additional Information
In connection with the transaction, Taro commenced disseminating the definitive Proxy Statement to shareholders on
Please refer to Taro’s press release dated
This announcement is neither a solicitation of proxy, an offer to purchase nor a solicitation of an offer to sell any securities, and it is not a substitute for any proxy statement or other materials that may be filed with or furnished to the
About
Forward-Looking Statements
This announcement contains forward-looking statements. Forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Statements that are not historical or current facts, including statements about beliefs and expectations, are forward-looking statements. Forward-looking statements involve factors, risks and uncertainties that could cause actual results to differ materially from those expressed or implied in these forward-looking statements. Such factors, risks and uncertainties include the possibility that the Merger will not occur on the timeline anticipated, or at all, if events arise that result in the termination of the Agreement, or if one or more of the various closing conditions to the Merger are not satisfied or waived, or if the regulatory review process takes longer than anticipated and other risks and uncertainties discussed in documents filed with the
Further information on these and other factors is included in filings the Company makes with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20240508411736/en/
Investor Relations Contacts
VP, CFO
(914) 345-9001
William.Coote@taro.com
Source: